Abstract: The present invention relates to optionally substituted, non-toxic peptides and derivatives capable of inhibiting superoxide production in phagocytic cells. The invention also relates to compositions and methods useful in inhibiting inflammation and in treating inflammatory disorders such as autoimmune disorders, gout, adult respiratory distress syndrome, asthma, myocardial infarction, and various dermatological disorders.The present invention contemplates compositions derived from low molecular weight GTP-binding proteins (LMWG), mastoparan, GAP proteins, and related peptides. The invention further contemplates compositions useful in inhibiting activation of NADPH oxidase or in promoting GDP/GTP exchange. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.
Abstract: The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.
Abstract: The present invention describes a rapid method for the identification of compounds/reagents which inhibit lipopolysaccharide (LPS) binding to LPS binding protein (LBP), and kits for practicing the method.
Type:
Grant
Filed:
March 2, 1994
Date of Patent:
January 6, 1998
Assignee:
The Scripps Research Institute
Inventors:
Douglas N. Mintz, Peter Tobias, Richard Ulevitch
Abstract: The present invention describes methods for producing metal binding sites on polypeptides, and particularly for producing metal binding sites within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles. The invention also describes oligonucleotides useful for preparing the metal binding sites, and human monoclonal antibodies produced by the present methods.
Type:
Grant
Filed:
June 14, 1993
Date of Patent:
October 21, 1997
Assignee:
The Scripps Research Institute
Inventors:
Carlos F. Barbas, Jonathan Rosenblum, Richard A. Lerner
Abstract: The present invention describes polypeptides and anti-peptide antibodies capable of inhibiting serine protease enzymatic activity. In particular, polypeptides and anti-peptide antibodies derived from the blood coagulation serine proteases Factor VIIa, Factor IXa, Factor Xa, Factor XIa, thrombin and plasma kallikrein are described that are capable of inhibiting coagulation. The polypeptide and antibody are useful in methods and systems for inhibiting serine proteases, and particularly for inhibiting blood coagulation processes mediated by serine proteases in vitro or in a human patient.
Abstract: The present invention describes methods for producing antibody libraries, and particularly for increasing antibody library diversity by inducing mutagenesis within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles comprising the library. The invention also describes oligonucleotides useful for increasing the library diversity, and universal light chains useful in the library production methods.
Type:
Grant
Filed:
September 2, 1994
Date of Patent:
September 16, 1997
Assignee:
The Scripps Research Institute
Inventors:
Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
Abstract: Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed. The antigens to which the antibodies of the invention are specific are characterized.
Abstract: The invention describes a metal binding protein capable of forming a coordination complex with a metal cation. The protein contains a sequence of amino acid residues that defines a variable domain of an immunoglobulin light chain having a L1 region and a L3 region, and also contains three contact amino acid residues in the variable domain that participate as ligands for the metal coordination complex.
Type:
Grant
Filed:
November 22, 1994
Date of Patent:
September 9, 1997
Assignee:
The Scripps Research Institute
Inventors:
Richard A. Lerner, Victoria A. Roberts, Elizabeth D. Getzoff, John A. Tainer, Stephen J. Benkovic